Cardiff Oncology Inc CRDF:NASDAQ

RT Quote | NASDAQ | USD
Last | 05/20/22 EDT
1.24quote price arrow down-0.04 (-3.12%)
Volume
337,911
52 week range
1.13 - 8.58
Loading...
  • Open1.31
  • Day High1.31
  • Day Low1.21
  • Prev Close1.24
  • 52 Week High8.58
  • 52 Week High Date09/09/21
  • 52 Week Low1.13
  • 52 Week Low Date05/11/22

Key Stats

  • Market Cap53.70M
  • Shares Out43.31M
  • 10 Day Average Volume0.57M
  • Dividend-
  • Dividend Yield-
  • Beta1.99
  • YTD % Change-79.37

KEY STATS

  • Open1.31
  • Day High1.31
  • Day Low1.21
  • Prev Close1.24
  • 52 Week High8.58
  • 52 Week High Date09/09/21
  • 52 Week Low1.13
  • 52 Week Low Date05/11/22
  • Market Cap53.70M
  • Shares Out43.31M
  • 10 Day Average Volume0.57M
  • Dividend-
  • Dividend Yield-
  • Beta1.99
  • YTD % Change-79.37

RATIOS/PROFITABILITY

  • EPS (TTM)-0.83
  • P/E (TTM)-1.49
  • Fwd P/E (NTM)-1.21
  • EBITDA (TTM)-34.124M
  • ROE (TTM)-26.78%
  • Revenue (TTM)360,000.00
  • Gross Margin (TTM)27.28%
  • Net Margin (TTM)-9,447.37%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date08/03/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Cardiff Oncology Inc

There is no recent news for this security.

Profile

MORE
Cardiff Oncology Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatment for cancer patients. Its drug candidate onvansertib, is a polo-like kinase 1 (PLK1) adenosine triphosphate (ATP) competitive inhibitor with the combination of chemotherapy and targeted therapeutics. Its clinical trial includes TROV-054, CRDF-001 and TROV-053. TROV-054 is a Phase I b/2 open-label clinical trial of onvansertib in combination with FOLFIRI (folinic...
Rodney Markin M.D., Ph.D.
Independent Chairman of the Board
Mark Erlander Ph.D.
Chief Executive Officer, Director
Vicki Kelemen
Chief Operating Officer
James Levine
Chief Financial Officer
Address
11055 Flintkote Ave
San Diego, CA
92121-1220
United States

Top Peers

SYMBOLLASTCHG%CHG
DBTX
Decibel Therapeutics Inc
2.35+0.08+3.52%
HEPA
Hepion Pharmaceuticals Inc
0.7235-0.0223-2.9901%
AKTX
Akari Therapeutics PLC
1.13UNCHUNCH
GMTX
Gemini Therapeutics Inc
1.36+0.01+0.74%
BLRX
BioLine RX Ltd
1.27UNCHUNCH